Endocrinology and Metabolism

Review Articles

Pituitary gland
Growth Hormone, Not Simply Just a Hormone for Growth: Kevin C. J. Yuen, Jaime Guevara-Aguirre, John J. Kopchick; Endocrinol Metab. 2026;41(1):34-48. Published online February 3, 2026; DOI: https://doi.org/10.3803/EnM.2025.2806

919 View
104 Download

Abstract PDF PubReader ePub: Since its discovery almost 100 years ago, growth hormone (GH) has been extensively studied to elucidate its structural characteristics, receptor interactions and its physiologic and non-physiologic effects. These actions include but are not limited to its effects on somatic growth, substrate metabolism, body composition, bone mineral density, cardiovascular system, and cognitive function. Contextually, recombinant human GH was approved for growth promotion in children and to enhance metabolic health in adult patients with GH deficiency (GHD), along with other clinical indications. Studies involving individuals and animal models exhibiting dysregulated GH levels, ranging from complete or partial GHD to GH excess, have unveiled a spectrum of several less evident GH actions. In this review, we exclude discussing the classic GH therapeutic applications but instead focus on the interplay between GH and glucose metabolism, fibrosis, and carcinogenesis that is observed with varying GH levels and action. We also discuss clinical data derived from studies in acromegaly and GHD patients (including individuals with congenital GH and insulin-like growth factor I [IGF-I] deficiencies), and attempt to integrate findings from cellular, animal and human studies with the aim of highlighting novel characteristics and underlying molecular pathways through which both GH and IGF-I exert their more subtle actions.

Adrenal gland
The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin: Eline C. Nijenhuis-Noort, Kirsten A. Berk, Sebastian J. C. M. M. Neggers, Aart J. van der Lely; Endocrinol Metab. 2024;39(1):83-89. Published online January 9, 2024; DOI: https://doi.org/10.3803/EnM.2024.101

135,039 View
1,381 Download
38 Web of Science
42 Crossref

This review intends to provide the reader with a practical overview of several (patho)physiological conditions in which knowledge of the interplay between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin is important. This might help treating physicians in making the right decisions on how to intervene and improve metabolism for the benefit of patients, and to understand why and how metabolism responds in their specific cases. We will specifically address the interplay between GH, IGF-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary.

Citations

Citations to this article as recorded by

Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Ruth Frampton, Samantha Hocking, Jennifer R. Snaith, Jerry R. Greenfield
Trends in Endocrinology & Metabolism.2026; 37(2): 135. CrossRef
Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Seyed Mostafa Rahimi, Abouzar Bagheri
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3335. CrossRef
Zhi-Shen Pill ameliorates impaired glucose tolerance by targeting pancreatic β-cell and adipocyte pathways
Yinshan Huang, Xuan Ren, Xiudao Song, Kaiwen Xu, Lijuan Jin, Hui Zhu, Wei Chen, Wei Mu, Chunbo Jiang, Guoqiang Liang
Journal of Ethnopharmacology.2026; 357: 120931. CrossRef
Human growth hormone‐induced mitotic maladaptation in podocytes and implications in diabetic kidney disease
Bharath Banoth, Sumathi Raviraj, Anil Kumar Pasupulati
Journal of Neuroendocrinology.2026;[Epub] CrossRef
Dairy intake and risk of type 2 diabetes and metabolic syndrome: A narrative review
Karani Santhanakrishnan Vimaleswaran, Viswanathan Mohan
Nutrition.2026; 144: 113064. CrossRef
Maternal diet shapes milk bile acids to regulate neonatal growth through TGR5
Lufuno Phophi, Haley M. Wilt, Zhengzheng Hu, Rishi Gadikota, Mallory Cadiz, Mikayla S. Manzi, Freddie D. Ortiz Martinez, Sarayu Vanga, Elizabeth G. Chapman, Scott A. Tibbetts, Stephanie M. Karst
Cell Reports.2026; 45(1): 116744. CrossRef
Dietary Defective Jujube as a Corn Substitute: Impacts on Growth Performance, Meat Traits, and Alternaria Toxin Exposure in Lambs
Letian Zhang, Haoyang Hui, Muhammad Faheem, Yanfeng Xue, Ning Chen, Xiaoling Zhou
Animals.2026; 16(2): 255. CrossRef
Insulin Receptor Family Autoantibodies in Patients with Type B Insulin Resistance
Jennifer E Lee, Thilo S Chillon, Waldemar B Minich, Brent S Abel, Marissa Lightbourne, Lutz Schomburg, Rebecca J Brown
The Journal of Clinical Endocrinology & Metabolism.2026;[Epub] CrossRef
The relationship between IGF-1 and cardiovascular diseases and the potential mediating role of TyG-related index: evidence from a cohort study
Haipeng Chen, Ning Huang, Yang Huang, Jin Chen, Xu Luo
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
IGF-1 as a mediator in the association between body mass index and risk of liver cancer: A prospective analysis of 432,203 participants from the UK biobank
Wenwen Yang, Zhixian Bao, Yuhua Chen, Jie Gao, Rui Ji
Growth Hormone & IGF Research.2026; 84: 101684. CrossRef
Associations of insulin-like growth factor 1 and IGF binding proteins 2 and 3 with lipids in toddlers
Johanna Neiß, Hans Demmelmair, Fabian Geyer, Alexander Triebswetter, Dudung Angkasa, Joaquin Escribano, Natalia Ferré, Mariona Gispert-Llauradó, Berthold Koletzko, Susanne Bechtold-Dalla Pozza, Veit Grote
Lipids in Health and Disease.2026;[Epub] CrossRef
Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
John A. D'Elia, Bijan Roshan, Larry A. Weinrauch
Journal of Diabetes and its Complications.2026; 40(4): 109289. CrossRef
Corrigendum to ‘What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?’ [JDC, Vol. 39, Issue 10, October 2025, 109132]
Maria Aurora Roma-Wilson, Paolo Pozzilli
Journal of Diabetes and its Complications.2026; 40(3): 109230. CrossRef
Insulin-Like Growth Factor Signaling in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies
Jie Miao, Yanli Zhang, Chen Su, Qiandan Zheng, Junhong Guo
Molecular Neurobiology.2025; 62(3): 3195. CrossRef
GHRH in diabetes and metabolism
Charlotte Steenblock, Stefan R. Bornstein
Reviews in Endocrine and Metabolic Disorders.2025; 26(3): 413. CrossRef
Signaling pathways and targeted therapies in Ewing sarcoma
Ke Jia, Li Cao, Yihan Yu, Doudou Jing, Wei Wu, Brian Andrew Van Tine, Zengwu Shao
Pharmacology & Therapeutics.2025; 266: 108765. CrossRef
Expanding the Clinical and Mutational Spectrum of Biallelic POC1A Variants: Characterization of Four Patients and a Comprehensive Review of POC1A‐Related Phenotypes
Umut Altunoglu, Gozde Tutku Turgut, Esin Karakılıç Özturan, Tuğba Kalaycı, Mert Kaya, Güven Toksoy, Firdevs Baş, Hülya Kayserili, Feyza Darendeliler
Clinical Genetics.2025; 107(4): 390. CrossRef
Bridging Pubertal Changes and Endotype Based Therapy in Type 1 Diabetes
M. A. Roma‐Wilson, R. Buzzetti, S. Zampetti
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
Training with electrical muscle stimulation: a novel method to improve Body Mass Index, lipid profile, growth hormone, and cortisol in overweight subjects
Elnaz RIYAHI, Jalil REISI, Sayyed M. MARANDI, Milad ABDOLLAHI
The Journal of Sports Medicine and Physical Fitness.2025;[Epub] CrossRef
Bilateral ovarian juvenile granulosa cell tumor in a neonate with Donohue syndrome: a case report and review of literature
Amany Reda Elbahbity, Amr Abdelhamid AbouZeid, Mohammad Hassan Mohamed, Mohammad Hassan Elibiary, Soha M. khafagy, Amira Mostafa Rashad, Shaimaa Mahmoud Abdelraouf, Sohair Abdelbaset Zayed, Manal Fawzy Gadalla, Shaimaa Abdelsattar Mohammad
Egyptian Pediatric Association Gazette.2025;[Epub] CrossRef
Association of IGF-1 and IGFBP-3 with metabolic abnormalities among children and adolescents
Zhenghao Zhao, Yuanyuan Ma, Xinyi Zhang, Xiaoxiao Liu, Yang Li, Zhongze Fang, Rongxiu Zheng, Jing Li
Frontiers in Endocrinology.2025;[Epub] CrossRef
Early Cardiovascular and Metabolic Benefits of rhGH Therapy in Adult Patients with Severe Growth Hormone Deficiency: Impact on Oxidative Stress Parameters
Maria Kościuszko, Angelika Buczyńska, Justyna Hryniewicka, Dorota Jankowska, Agnieszka Adamska, Katarzyna Siewko, Małgorzata Jacewicz-Święcka, Marcin Zaniuk, Adam Jacek Krętowski, Anna Popławska-Kita
International Journal of Molecular Sciences.2025; 26(12): 5434. CrossRef
Effects of warm-season feeding on yak growth, antioxidant capacity, immune function, and fecal microbiota
Yining Xie, Yangji Cidan, Zhuoma Cisang, Deji Gusang, Quzha Danzeng, Wangdui Basang, Yanbin Zhu, Jinshui Lin, Lizhuang Hao, Tariq Shah
Microbiology Spectrum.2025;[Epub] CrossRef
Post-Exercise Whey Protein Supplementation: Effects on IGF-1, Strength, and Body Composition in Pre-Menopausal Women, a Randomised Controlled Trial
Marc Murray, Lara Vlietstra, Alyssa M. D. Best, Stacy T. Sims, James A. Loehr, Nancy J. Rehrer
Nutrients.2025; 17(12): 2033. CrossRef
Diagnostic accuracy of triglyceride to glucose index and triglyceride/high-density lipoprotein index for insulin resistance among children and adolescents: A systematic review
Miguel Cabanillas-Lazo, Carlos Quispe-Vicuña, Milagros Pascual-Guevara, Claudia Cruzalegui-Bazán, Arturo Duran-Pecho, José Paz-Ibarra, Victor Velásquez-Rimachi, Qian Wu
PLOS One.2025; 20(6): e0326179. CrossRef
Diabetes and Bone Health: A Comprehensive Review of Impacts and Mechanisms
Prabhat Upadhyay, Sudhir Kumar
Diabetes/Metabolism Research and Reviews.2025;[Epub] CrossRef
High Blood Lead Levels as A Risk Factor of Stunting: A Study of Children in Agricultural Areas
Alfan Afandi, Suhartono Suhartono, Budiyono Budiyono, Ani Margawati, Apoina Kartini
JURNAL KESEHATAN LINGKUNGAN .2025; 17(1): 45. CrossRef
Viral Infections in Type 2 Diabetes: A Dangerous Liaison
Azizul Haque, Anudeep B. Pant
Viruses.2025; 17(9): 1150. CrossRef
Intranasal nanoparticle therapy for arsenic-induced neurotoxicity: Restoring IGF-1 signaling and advancing translational neuroprotection
Nourhan Elsayed, Jhi Biau Foo
Neuroscience.2025; 585: 107. CrossRef
Serum IGF-1 May be less reliable when assessing the GH-IGF-1 axis in the elderly
Angelo Milioto, Gudmundur Johannsson, Daniela Esposito
Pituitary.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
Ralf Weiskirchen, Amedeo Lonardo
International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Regenerative therapeutic effects of conditioned medium from human umbilical cord‑derived mesenchymal stem cells as an adjuvant to insulin therapy in a rat model of type 2 diabetes
Siufui Hendrawan, Jennifer Lheman, Olivia Marcelina, Lydia Tantoso, Hans Baer, Shirly Gunawan
World Academy of Sciences Journal.2025; 7(6): 1. CrossRef
Prevalence of Liver Steatosis and Fibrosis Assessed by Transient Elastography in a High Cardiovascular-Risk Outpatient Cohort Including T1DM and T2DM Patients
Alina N. Saidi, Willy B. Theel, Diederick E. Grobbee, Aart-Jan van der Lely, Femme Dirksmeier-Harinck, Marco Alings, Ellen van der Zwan-van Beek, Simone P. Rauh, Moniba Rasheed, Manuel Castro Cabezas
Diabetology.2025; 6(11): 129. CrossRef
Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus
Viviana Elian, Violeta Popovici, Mihnea Ioan Nicolescu, Alexandra Maria Nicolescu, Sorina Maria Aurelian, Emma Adriana Ozon
Current Issues in Molecular Biology.2025; 47(11): 929. CrossRef
Adverse events with usage of human growth hormone: a review
Ludwik K. Branski, Sarita Thanedar, Nafis Deen, Kevin W. Cho, Gongkai Liu, Gabriel Hundeshagen, David N. Herndon, Linda E. Sousse
Discover Medicine.2025;[Epub] CrossRef
Unlocking Gut-Driven Metabolic Repair: The Role of Glucomannan Porang (Amorphophallus muelleri Blume) in Insulin Resistance and Short-Chain Fatty Acid Modulation in a Type 2 Diabetes Mellitus Rat Model
Azizah H. Safitri, Rahmata A. Sayyida, Eni Widayati, Nurina Tyagita
Tropical Journal of Natural Product Research.2025;[Epub] CrossRef
Effects of Short-Term (20-Day) Alternate-Day Modified Fasting and Time-Restricted Feeding on Fasting Glucose and IGF-1 in Obese Young Women
Dian Aristia Rachmayanti, Purwo Sri Rejeki, Raden Argarini, Hermina Novida, Sri Soenarti, Shariff Halim, Chy’as Diuranil Astrid Permataputri, Sheeny Priska Purnomo
Diseases.2025; 13(12): 390. CrossRef
Human Cancers Derived from Either Genetic or Lifestyle Factors Are Initiated by Impaired Estrogen Signaling
Zsuzsanna Suba
Cancers.2025; 18(1): 78. CrossRef
IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review
Justyna Szydlowska-Gladysz, Adrianna Edyta Gorecka, Julia Stepien, Izabela Rysz, Iwona Ben-Skowronek
International Journal of Molecular Sciences.2024; 25(7): 3966. CrossRef
Insulin resistance reduction, intermittent fasting, and human growth hormone: secondary analysis of a randomized trial
Benjamin D. Horne, Jeffrey L. Anderson, Heidi T. May, Tami L. Bair, Viet T. Le, Leslie Iverson, Kirk U. Knowlton, Joseph B. Muhlestein
npj Metabolic Health and Disease.2024;[Epub] CrossRef
Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin
Kevin C. J. Yuen, Rikke Hjortebjerg, Ashok Ainkaran Ganeshalingam, David R. Clemmons, Jan Frystyk
Frontiers in Endocrinology.2024;[Epub] CrossRef
Comprehensive Management of Diabetes Mellitus in the Elderly: A Review
Bharat Kumar, Ravi Kant, Gopal Krishana Bohra
Journal of Cardio-diabetes and Metabolic Disorders.2023; 3(2): 21. CrossRef

Mineral, Bone & Muscle
Acromegaly and Bone: An Update: Andrea Giustina; Endocrinol Metab. 2023;38(6):655-666. Published online December 22, 2023; DOI: https://doi.org/10.3803/EnM.2023.601

14,234 View
377 Download
28 Web of Science
30 Crossref

Abstract PDF PubReader ePub

Since our discovery in 2006 that acromegaly is associated with an increased risk of vertebral fractures, many authors have confirmed this finding in both cross-sectional and prospective studies. Due to the high epidemiological and clinical impact of this newly discovered comorbidity of acromegaly, this topic has progressively become more important and prominent over the years, and the pertinent literature has been enriched by new findings on the pathophysiology and treatment. The aim of this narrative review was to discuss these novel findings, integrating them with the seminal observations, in order to give the reader an updated view of how the field of acromegaly and bone is developing, from strong clinical observations to a mechanistic understanding and possible prevention and treatment.

Citations

Citations to this article as recorded by

Integrative Machine Learning Approach for Predicting Resistance to First-generation Receptor Ligands in Acromegaly
Wei Lin, Songchang Shi, Yuanyuan Zheng, Edward Laws, Timothy R Smith, Le Min
The Journal of Clinical Endocrinology & Metabolism.2026; 111(2): 484. CrossRef
Association between vertebral fracture risk and bone mineral density in patients with acromegaly
Shuaiming Chen, Min Liu, Huiwen Tan, Lin Ji, Yerong Yu, Shu Jiang, Bowen Cai, Wei Wang, Songping Zheng, Xin Zan, Huan Xu, Jing Li, Jianwei Li
Pituitary.2026;[Epub] CrossRef
The Journey of Acromegaly Towards Treatment: A Single-Center Study
Varvara Chalmantzi, Sophia Vlachou, Maria Eleni Chondrogianni, Maria Panagaki, Ariadni Spyroglou, Marina Tsoli, Eva Kassi, Gregory Kaltsas, Krystallenia I. Alexandraki
Journal of Personalized Medicine.2026; 16(2): 85. CrossRef
Cancer Risk in Patients with Acromegaly: Insights from a Single Center in Ankara
Murat Cinel, Ozgur Demir, Rovsan Hasenov, Sule Canlar, Caglar Keskin, Asena Gökçay Canpolat, Mustafa Sahin, Sevim Güllü, Demet Corapcioglu
Journal of Clinical Medicine.2026; 15(4): 1573. CrossRef
Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach
Alessandro Giustina, Andrea Giustina
Reviews in Endocrine and Metabolic Disorders.2025; 26(1): 1. CrossRef
Long-Term Prognosis and Systemic Impact of Acromegaly: Analyses Utilizing Korean National Health Insurance Data
Sangmo Hong, Kyungdo Han, Cheol-Young Park
Endocrinology and Metabolism.2025; 40(1): 1. CrossRef
Frailty and pituitary surgery: a systematic review
Mendel Castle-Kirszbaum, Ann McCormack, Christopher Ovenden, Jeremy Kam, James King, Yi Yuen Wang, Tony Goldschlager
Pituitary.2025;[Epub] CrossRef
Artificial intelligence in acromegaly: Why, when and how
Alessandro Giustina, Andrea Giustina
Pituitary.2025;[Epub] CrossRef
Muscle dysfunction is associated with poor quality of life in long-term controlled patients with acromegaly
Luciana Martel-Duguech, Helena Bascuñana, Jordi Cuartero, Susan M. Webb, Elena Valassi
Pituitary.2025;[Epub] CrossRef
Evaluation of bone density and microstructure by DXA, TBS and HR-pQCT: an assessment of cortical porosity and its association with vertebral fractures in patients with acromegaly
PG Ornellas, EMF Gama, LMC Mendonça, C Villela-Nogueira, FP Paranhos-Neto, L Kasuki, MR Gadelha, MLF Farias, M Madeira
Journal of Endocrinological Investigation.2025; 48(9): 2087. CrossRef
Growth Hormone and Bone: Preclinical and Clinical Perspectives
Kevin C.J. Yuen
Endocrine Practice.2025; 31(9): 1197. CrossRef
Development and application of HDA-ABi-GRU-based on the interpersonal problems scale of personality disorders in acromegaly patients
Shashi Kiran Tagilapalli, Lei Shi, Zhentian Wu, Canhui Tian, Yanmei Tie, Dongsheng He, Haijun Wang, Wenli Chen
Neurocomputing.2025; 653: 131138. CrossRef
Collaboration Between Endocrinologists and Dentists in the Care of Patients with Acromegaly—A Narrative Review
Beata Wiśniewska, Kosma Piekarski, Sandra Spychała, Ewelina Golusińska-Kardach, Maria Stelmachowska-Banaś, Marzena Wyganowska
Journal of Clinical Medicine.2025; 14(15): 5511. CrossRef
Skeletal Health in Pituitary and Neuroendocrine Diseases: Prevention and Treatments of Bone Fragility
Flavia Costanza, Antonella Giampietro, Laura De Marinis, Antonio Bianchi, Sabrina Chiloiro, Alfredo Pontecorvi
Targets.2025; 3(3): 26. CrossRef
Consensus on acromegaly therapeutic outcomes: an update
Shlomo Melmed, Luigi di Filippo, Maria Fleseriu, Moisés Mercado, Niki Karavitaki, Mark Gurnell, Roberto Salvatori, Stylianos Tsagarakis, Marco Losa, Pietro Maffei, Alberto M. Pereira, Eliza B. Geer, Laurence Katznelson, Aart Jan van der Lely, Jens Bollers
Nature Reviews Endocrinology.2025; 21(11): 718. CrossRef
ACROMEGALY – ETIOLOGY, SYMPTOMS, TREATMENT. LITERATURE REVIEW
Michał Ochwat, Katarzyna Dąbek, Aleksandra Kajtel, Anna Skowronek, Martyna Piekarska-Magiera, Adam Sielicki, Maria Ochwat, Tomasz Skowronek, Michał Oborski, Zofia Sudoł
International Journal of Innovative Technologies in Social Science.2025;[Epub] CrossRef
Acromegaly treatment and bone: a bidirectional relationship
Sabrina Chiloiro, Chiara Palumbo, Antonella Giampietro, Laura De Marinis, Antonio Bianchi, Andrea Giustina, Alfredo Pontecorvi
Pituitary.2025;[Epub] CrossRef
Dental Implantology in Acromegaly: Pathophysiological Challenges, Biomaterial Interactions, and Future Directions—A Narrative Review
Beata Wiśniewska, Sandra Spychała, Kosma Piekarski, Ewelina Golusińska-Kardach, Maria Stelmachowska-Banaś, Marzena Wyganowska
Journal of Functional Biomaterials.2025; 16(11): 411. CrossRef
New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases
Luigi di Filippo, John P. Bilezikian, Ernesto Canalis, Umberto Terenzi, Andrea Giustina
Endocrine.2024; 85(3): 1007. CrossRef
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience
Sabrina Chiloiro, Antonella Giampietro, Amato Infante, Pier Paolo Mattogno, Liverana Lauretti, Alessandro Olivi, Laura De Marinis, Alfredo Pontecorvi, Francesco Doglietto, Antonio Bianchi
Pituitary.2024; 27(3): 303. CrossRef
Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)
Andrea Giustina, M. M. Uygur, S. Frara, A. Barkan, N. R. Biermasz, P. Chanson, P. Freda, M. Gadelha, L. Haberbosch, U. B. Kaiser, S. Lamberts, E. Laws, L. B. Nachtigall, V. Popovic, M. Reincke, A. J. van der Lely, J. A. H. Wass, S. Melmed, F. F. Casanueva
Pituitary.2024; 27(4): 381. CrossRef
Vertebral fractures in patients with non-functioning pituitary adenomas - a new frontier?
Nicholas A. Tritos
Pituitary.2024; 27(4): 311. CrossRef
Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report
Tongxin Xiao, Xinxin Mao, Ou Wang, Yong Yao, Kan Deng, Huijuan Zhu, Lian Duan
BMC Endocrine Disorders.2024;[Epub] CrossRef
Skeletal fragility in pituitary disease: how can we predict fracture risk?
Fabio Bioletto, Alessandro Maria Berton, Marco Barale, Luigi Simone Aversa, Lorenzo Sauro, Michela Presti, Francesca Mocellini, Noemi Sagone, Ezio Ghigo, Massimo Procopio, Silvia Grottoli
Pituitary.2024; 27(6): 789. CrossRef
Vitamin D in pituitary driven osteopathies
Sabrina Chiloiro, Flavia Costanza, Elena Riccardi, Antonella Giampietro, Laura De Marinis, Antonio Bianchi, Alfredo Pontecorvi, Andrea Giustina
Pituitary.2024; 27(6): 847. CrossRef
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study
Sabrina Chiloiro, Flavia Costanza, Antonella Giampietro, Amato Infante, Pier Paolo Mattogno, Flavia Angelini, Consolato Gullì, Liverana Lauretti, Mario Rigante, Alessandro Olivi, Laura De Marinis, Francesco Doglietto, Antonio Bianchi, Alfredo Pontecorvi
Frontiers in Endocrinology.2024;[Epub] CrossRef
Growth hormone and bone: a basic perspective
Simona Bolamperti, Isabella Villa, Luigi di Filippo
Pituitary.2024; 27(6): 745. CrossRef
Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management
Iris C. M. Pelsma, Herman M. Kroon, Cornelie D. Andela, Enrike M. J. van der Linden, Margreet Kloppenburg, Nienke R. Biermasz, Kim M. J. A. Claessen
Pituitary.2024; 27(6): 824. CrossRef
Modern approach to bone comorbidity in prolactinoma
Meliha Melin Uygur, Sara Menotti, Simona Santoro, Andrea Giustina
Pituitary.2024; 27(6): 802. CrossRef
Novel approach to bone comorbidity in resistant acromegaly
Stefano Frara, Matteo Acanfora, Vincenzo Franzese, Maria Luisa Brandi, Marco Losa, Andrea Giustina
Pituitary.2024; 27(6): 813. CrossRef

Original Article

Clinical Study
Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma: Hyein Jung, Kyungwon Kim, Daham Kim, Ju Hyung Moon, Eui Hyun Kim, Se Hoon Kim, Cheol Ryong Ku, Eun Jig Lee; Endocrinol Metab. 2021;36(2):342-350. Published online March 23, 2021; DOI: https://doi.org/10.3803/EnM.2020.875

8,684 View
168 Download
18 Web of Science
17 Crossref

Abstract PDF PubReader ePub

Background
The guanine nucleotide-binding protein, alpha stimulating (GNAS) gene has been associated with growth hormone (GH)-secreting pituitary adenoma. We investigated the prevalence of GNAS mutations in Korean patients with acromegaly and assessed whether mutation status correlated with biochemical or clinical characteristics.
Methods
We studied 126 patients with acromegaly who underwent surgery between 2005 and 2014 at Severance Hospital. We performed GNAS gene analysis and evaluated age, sex, hormone levels, postoperative biochemical remission, and immunohistochemical staining results of the tumor.
Results
GNAS mutations were present in 75 patients (59.5%). Patients with and without GNAS mutations showed similar age distribution and Knosp classification. The proportion of female patients was 76.5% and 48.0% in the GNAS-negative and GNAS-mutation groups, respectively (P=0.006). In immunohistochemical staining, the GNAS-mutation group showed higher GH expression in pituitary tumor tissues than the mutation-negative group (98.7% vs. 92.2%, P=0.015). Patients with GNAS mutations had higher preoperative insulin-like growth factor-1 levels (791.3 ng/mL vs. 697.0 ng/mL, P=0.045) and lower immediate postoperative basal (0.9 ng/mL vs. 1.0 ng/mL, P=0.191) and nadir GH levels (0.3 ng/mL vs. 0.6 ng/mL, P=0.012) in oral glucose tolerance tests. Finally, the GNAS-mutation group showed significantly higher surgical remission rates than the mutation-negative group, both at 1 week and 6 months after surgical resection (70.7% vs. 54.9%, P=0.011; 85.3% vs. 82.4%, P=0.007, respectively).
Conclusion
GNAS mutations in GH-secreting pituitary tumors are associated with higher preoperative insulin-like growth factor-1 levels and surgical remission rates and lower immediate postoperative nadir GH levels. Thus, GNAS mutation status can predict surgical responsiveness in patients with acromegaly.

Citations

Citations to this article as recorded by

Clinical characteristics associated with somatic GNAS mutations in acromegaly: a systematic review and institutional experience
Brendan R. Dillon, Margaret Ruddy, Emily C. McQuade, Shruti N. Shah, Alberta Twi-Yeboah, Benjamin A. Levinson, Nidhi Agrawal
Frontiers in Endocrinology.2026;[Epub] CrossRef
Molecular biology of pituitary neuroendocrine tumors
Reilly L. Kidwell, James Trippett, Manish K. Aghi
Journal of Neuro-Oncology.2026;[Epub] CrossRef
Rapid intraoperative boundary diagnosis of somatotroph pituitary neuroendocrine tumors using real-time PCR
Yoshiki Sato, Kazuhito Takeuchi, Fumiharu Ohka, Yuichi Nagata, Sachi Maeda, Tomoki Matsuyama, Toshiaki Hirose, Shoichi Deguchi, Eriko Okumura, Kenichiro Iwami, Ryuta Saito
Acta Neuropathologica Communications.2026;[Epub] CrossRef
Contract to kill: GNAS mutation
Pratima Raut, Poompozhil Mathivanan, Surinder K. Batra, Moorthy P. Ponnusamy
Molecular Cancer.2025;[Epub] CrossRef
Benign tumors broaden the field of application for immunotherapy
Mohamed A. Youssef, Hisham Al-Sharif, Brian T. McGrath, Maria M. Picken, I. Caroline Le Poole
Frontiers in Immunology.2025;[Epub] CrossRef
Progress in the pathogenesis and treatment of pituitary neuroendocrine tumors (PitNETs): From molecular mechanisms to emerging therapies
Na Wu, Naijia Wu, Nan Wang, Yonghong Zhu
Molecular and Cellular Probes.2025; 83: 102039. CrossRef
Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression
Wan Su, Zhang Ye, Jifang Liu, Kan Deng, Jinghua Liu, Huijuan Zhu, Lian Duan, Chen Shi, Linjie Wang, Yuxing Zhao, Fengying Gong, Yi Zhang, Bo Hou, Hui You, Feng Feng, Qing Ling, Yu Xiao, Yongdong Guo, Wenyi Fan, Sumei Zhang, Zixin Zhang, Xiaomin Hu, Yong Y
Nature Communications.2025;[Epub] CrossRef
Unraveling the link between GNAS R201 mutation and colorectal cancer
Mohammad Amin Behmanesh, Paniz Rafiee, Forough Eidikhosh, Abbas Moridnia
Scientific Reports.2025;[Epub] CrossRef
The PitNET Puzzle: From Zero to Linking Molecular Behavior with Neurosurgical Aspects
Amira Kamel, Ligia Gabriela Tataranu, Bianca-Cristina Cristutiu, Anica Dricu, Radu Eugen Rizea
Medicina.2025; 61(11): 1973. CrossRef
Genetic diagnosis in acromegaly and gigantism: From research to clinical practice
Claudia Ramírez-Rentería, Laura C. Hernández-Ramírez
Best Practice & Research Clinical Endocrinology & Metabolism.2024; 38(3): 101892. CrossRef
Unlocking the Genetic Secrets of Acromegaly: Exploring the Role of Genetics in a Rare Disorder
Ioana Balinisteanu, Lavinia Caba, Andreea Florea, Roxana Popescu, Laura Florea, Maria-Christina Ungureanu, Letitia Leustean, Eusebiu Vlad Gorduza, Cristina Preda
Current Issues in Molecular Biology.2024; 46(8): 9093. CrossRef
Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas
Dingkai Xu, Ling Wang, Maohua Zheng
Immunity, Inflammation and Disease.2024;[Epub] CrossRef
GNAS mutations suppress cell invasion by activating MEG3 in growth hormone–secreting pituitary adenoma
CHAO TANG, CHUNYU ZHONG, JUNHAO ZHU, FENG YUAN, JIN YANG, YONG XU, CHIYUAN MA
Oncology Research.2024; 32(6): 1079. CrossRef
CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
Haruto Nishida, Yoshihiko Kondo, Takahiro Kusaba, Kazuhiro Kawamura, Yuzo Oyama, Tsutomu Daa, Avaniyapuram Kannan Murugan
PLOS ONE.2023; 18(2): e0281647. CrossRef
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing Liu
Thoracic Cancer.2023; 14(20): 1980. CrossRef
Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine
Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee
Endocrinology and Metabolism.2023; 38(5): 463. CrossRef
Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors
Mariana Torres-Morán, Alexa L. Franco-Álvarez, Rosa G. Rebollar-Vega, Laura C. Hernández-Ramírez
Cancers.2023; 15(23): 5685. CrossRef

Brief Reports

Hypothalamus and Pituitary gland
Reference Ranges of Serum Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3: Results from a Multicenter Study in Healthy Korean Adults: In-Kyung Jeong, Jong Kyu Byun, Junghyun Noh, Sang Wan Kim, Yoon-Sok Chung, Tae Sun Park, Sung-Woon Kim; Endocrinol Metab. 2020;35(4):954-959. Published online December 1, 2020; DOI: https://doi.org/10.3803/EnM.2020.785

9,564 View
173 Download
5 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Insulin-like growth factor-I (IGF-I) plays a pivotal role in the diagnosis and treatment of growth hormone (GH) excess or deficiency. The GH study group of the Korean Endocrine Society aims to establish the Korean reference ranges of serum IGF-I and insulin-like growth factor binding protein-3 (IGFBP-3) and assess the relationship between IGF-I and IGFBP-3 and clinical parameters. Fasting serum was collected from healthy Korean adults at health promotion centers of five hospitals nationwide. Serum IGF-I and IGFBP-3 were measured via an immunoradiometric assay using a DSL kit (Diagnostic Systems Laboratories). Serum samples from 354 subjects (180 male, 174 female) were analyzed based on sex at 10-year intervals from 21 to 70 years. IGF-I levels were inversely correlated with age. After adjustment of age, the IGF-I/IGFBP-3 ratio was significantly negatively associated with blood pressure and free thyroxine and positively associated with weight, hemoglobin, creatinine, alanine transferase, fasting glucose, and thyroid stimulating hormone. Therefore, age- and sex-specific reference ranges of serum IGF-I and IGFBP-3 can be efficient in evaluating GH excess or deficiency in Korean population.

Citations

Citations to this article as recorded by

Surgical outcomes of endoscopic endonasal surgery for nonfunctioning pituitary adenoma in elderly patients: a comprehensive analysis beyond age
Sun Mo Nam, Jong Ha Hwang, Hye Seok Park, Seung Shin Park, Jung Hee Kim, Min-Sung Kim, Chul-Kee Park, Hee-Pyoung Park, Yong Hwy Kim
BMC Endocrine Disorders.2026;[Epub] CrossRef
Serum IGF-1 and IGFBP-3 levels in healthy Korean men aged 19–40 years: a cross-sectional analysis of reference ranges and seasonal variation
Soo-Min Jung, Shi-Hyang Lee, Hyoeun Lee, Eun Na Kim, Kyun-Seop Bae
Translational and Clinical Pharmacology.2025; 33(3): 145. CrossRef
Association of Uterine Leiomyoma with Type 2 Diabetes Mellitus in Young Women: A Population-Based Cohort Study
Ji-Hee Sung, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
Diabetes & Metabolism Journal.2024; 48(6): 1105. CrossRef
Capillary blood as a complementary matrix for doping control purposes. Application to the definition of the individual longitudinal profile of IGF-1
Carlotta Stacchini, Francesco Botrè, Xavier de la Torre, Monica Mazzarino
Journal of Pharmaceutical and Biomedical Analysis.2023; 227: 115274. CrossRef

Hypothalamus and Pituitary gland
Establishment of Reference Intervals for Serum Insulin-Like Growth Factor I in Korean Adult Population: Boyeon Kim, Yonggeun Cho, Cheol Ryong Ku, Sang-Guk Lee, Kyung-A Lee, Jeong-Ho Kim; Endocrinol Metab. 2020;35(4):960-964. Published online November 20, 2020; DOI: https://doi.org/10.3803/EnM.2020.732

8,224 View
123 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Appropriate reference intervals of serum insulin-like growth factor I (IGF-I) is important for diagnosing and monitoring patients with growth hormone-related diseases. To establish reference intervals, adult individuals (n=1,334, 680 men and 654 women) were divided into six age groups (20–29, 30–39, 40–49, 50–59, 60–69, ≥70). Serum IGF-I was measured by chemiluminescence immunoassay (Liaison). Concordance of patient classification based on reference intervals, manufacturer’s intervals, and standard deviation score (SDS) was evaluated. New reference intervals had higher upper and lower limits than those specified by the manufacturer. The agreement between classification using new reference interval and the manufacturer’s reference interval, and that using new reference interval and SDS was 75.0% (weighted kappa, 0.17), 91.9% (weighted kappa, 0.51) in men and 91.0% (weighted kappa, 0.41), 92.5% (weighted kappa, 0.53) in women, respectively. Reference intervals should be established not only based on age and sex, but also on ethnicity and assay method.

Citations

Citations to this article as recorded by

Challenges of insulin-like growth factor-1 testing
Rongrong Huang, Junyan Shi, Ruhan Wei, Jieli Li
Critical Reviews in Clinical Laboratory Sciences.2024; 61(5): 388. CrossRef
Establishment of IGF-1 and IGFBP-3 continuous reference percentiles from data of healthy children using three kinds of immunoassay systems
Yongseok Jo, Kyungchul Song, Seok-Jae Heo, Junghwan Suh, Hyun Wook Chae, John Hoon Rim, Yongjung Park, Jong Baek Lim, Ho-Seong Kim, Jeong-Ho Kim
Heliyon.2024; 10(19): e38245. CrossRef
Male Idiopathic Hypogonadotropic Hypogonadism
Nastaran Salehisedeh, Amir Parhizkar, Parichehreh Yaghmaei, Marjan Sabbaghian
Journal of Human Reproductive Sciences.2022; 15(4): 351. CrossRef
Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly
In-Ho Jung, Seonah Choi, Cheol Ryong Ku, Sang-Guk Lee, Eun Jig Lee, Sun Ho Kim, Eui Hyun Kim
The Journal of Clinical Endocrinology & Metabolism.2021; 106(7): e2589. CrossRef

Original Article

Endocrine Research
Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas: Jean Kim, Ju Hun Oh, Heather Harlem, Michael D. Culler, Cheol Ryong Ku, Eun Jig Lee; Endocrinol Metab. 2020;35(1):177-187. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.177

8,441 View
121 Download
5 Web of Science
6 Crossref

Abstract PDF PubReader ePub

Background

Acromegaly is a rare disease primarily caused by growth hormone (GH)-secreting pituitary adenomas, and its treatment is costly. Moreover, some patients are unresponsive to treatment. Hence, there are increasing efforts to develop new drugs with improved effectiveness for this disease. BIM23B065 is a novel chimeric molecule that acts on both somatostatin and dopamine receptors. This study aimed to investigate the effects of BIM23B065 compared with those of a somatostatin receptor analog and a dopamine agonist.

Methods

The effects of BIM23B065 on the proliferation, GH and insulin-like growth factor-1 (IGF-1) levels, and extracellular signal-regulated kinase (ERK) 1/2 and cyclic AMP response element binding (CREB) phosphorylation of GH3 cells were investigated with MTS assay, enzyme-linked immunosorbent assay, and Western blotting, respectively. The dosage and treatment duration of BIM23B065 were tested in animal models of GH-secreting pituitary adenoma. The effect of BIM23B065 (3 mg/kg/day) on changes in IGF-1 levels before and after treatment was further investigated.

Results

In vitro, BIM23B065 treatment decreased GH release in the culture media and downregulated ERK 1/2 and CREB phosphorylation to 22% and 26%, respectively. In vivo, IGF-1 expression decreased to 50 % after 4 weeks of treatment with BIM23B065 using an osmotic pump implant. Moreover, magnetic resonance imaging results showed that the tumor size decreased significantly following treatment with BIM23B065 for 4 weeks.

Conclusion

The novel chimeric molecule was effective in decreasing IGF-1 and GH levels and may serve as an effective therapeutic agent for acromegaly.

Citations

Citations to this article as recorded by

Targeting dopamine pathways with hybrid molecules: Emerging outlook for cancer treatment
Piotr Koch, Natalia Pielaszkiewicz, Krystian Małek, Wojciech Kamysz, Patrycja Kleczkowska
European Journal of Pharmaceutics and Biopharmaceutics.2026; 222: 115031. CrossRef
Pituitary Tumorigenesis—Implications for Management
Rodanthi Vamvoukaki, Maria Chrysoulaki, Grigoria Betsi, Paraskevi Xekouki
Medicina.2023; 59(4): 812. CrossRef
Current and Emerging Medical Therapies in Pituitary Tumors
Nicolas Sahakian, Frédéric Castinetti, Thierry Brue, Thomas Cuny
Journal of Clinical Medicine.2022; 11(4): 955. CrossRef
Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells
Thomas Cuny, Thomas Graillon, Célines Defilles, Rakesh Datta, Shengwen Zhang, Dominique Figarella-Branger, Henry Dufour, Grégory Mougel, Thierry Brue, Tanya Landsman, Heather A. Halem, Michael D. Culler, Anne Barlier, Alexandru Saveanu
Pituitary.2021; 24(3): 351. CrossRef
Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study
Alessandra Dicitore, Maria Celeste Cantone, Germano Gaudenzi, Davide Saronni, Silvia Carra, Maria Orietta Borghi, Manuela Albertelli, Diego Ferone, Leo J. Hofland, Luca Persani, Giovanni Vitale
Neuroendocrinology.2021; 111(10): 937. CrossRef
Emerging drugs for the treatment of acromegaly
Claudia Campana, Giuliana Corica, Federica Nista, Francesco Cocchiara, Giulia Graziani, Keyvan Khorrami, Marta Franco, Mara Boschetti, Diego Ferone, Federico Gatto
Expert Opinion on Emerging Drugs.2020; 25(4): 409. CrossRef

Case Reports

Adrenal gland
Multiple Myeloma in a Patient with Acromegaly: Yu Mi Kang, Jong Han Choi, Min Jung Lee, Ari Ahn, Chan-Jeoung Park, Kiju Chang, Seyoung Seo, Sun In Hong, Min-Seon Kim; Endocrinol Metab. 2015;30(1):110-115. Published online March 27, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.1.110

9,678 View
39 Download
3 Web of Science
2 Crossref

Abstract PDF PubReader

Acromegaly is a slowly progressing condition resulting from excess growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. Cancer is the third most common cause of mortality in patients with acromegaly, and insulin-like growth factor 1 (IGF-1) is known to influence tumor formation by increasing cell proliferation and inhibiting apoptosis. Multiple myeloma (MM) is a plasma cell neoplasm, and previous studies have suggested the possible role of IGF-1 in its development of MM. However, no cases of acromegaly accompanied with MM have been reported in Asia to date. We here report the case of a 58-year-old woman with acromegaly accompanied with MM who presented with longstanding acromegalic manifestations resulting from a GH-secreting pituitary adenoma and also exhibited anemia, a reversed albumin/globulin ratio, and plasmacytosis on bone marrow examination. Because IGF-1 has been suggested to play an important role in the development and progression of MM, the patient promptly underwent surgical removal of the pituitary adenoma via a transsphenoidal approach. Since there is currently no consensus on therapeutic guidelines and suggested prognosis for MM with acromegaly, long-term follow-up of such cases is needed.

Citations

Citations to this article as recorded by

Hematological Malignancy in a Hypophysectomised Acromegalic Patient Under 4-Year Therapy with Somatostatin Analogues: From a Rib Lump Underlying Bone Plasmatocytoma Features to Multiple Myeloma
Mihaela Stanciu, Alina Cătană, Ruxandra Paula Ristea, Denisa Tanasescu, Mara Carsote, Florina Ligia Popa, Ioana-Codruța Lebădă
Diagnostics.2025; 15(20): 2623. CrossRef
Co-Occurrence of Acromegaly and Hematological Disorders: A Myth or Common Pathogenic Mechanism
Prakamya Gupta, Pinaki Dutta
Integrative Medicine International.2017; 4(1-2): 94. CrossRef

Adrenal gland
Acromegaly with Normal Insulin-Like Growth Factor-1 Levels and Congestive Heart Failure as the First Clinical Manifestation: Hyae Min Lee, Sun Hee Lee, In-Ho Yang, In Kyoung Hwang, You Cheol Hwang, Kyu Jeung Ahn, Ho Yeon Chung, Hui-Jeong Hwang, In-Kyung Jeong; Endocrinol Metab. 2015;30(3):395-401. Published online December 9, 2014; DOI: https://doi.org/10.3803/EnM.2015.30.3.395

8,093 View
51 Download
10 Web of Science
7 Crossref

Abstract PDF PubReader

The leading cause of morbidity and mortality in patients with acromegaly is cardiovascular complications. Myocardial exposure to excessive growth hormone can cause ventricular hypertrophy, hypertension, arrhythmia, and diastolic dysfunction. However, congestive heart failure as a result of systolic dysfunction is observed only rarely in patients with acromegaly. Most cases of acromegaly exhibit high levels of serum insulin-like growth factor-1 (IGF-1). Acromegaly with normal IGF-1 levels is rare and difficult to diagnose. Here, we report a rare case of an acromegalic patient whose first clinical manifestation was severe congestive heart failure, despite normal IGF-1 levels. We diagnosed acromegaly using a glucose-loading growth hormone suppression test. Cardiac function and myocardial hypertrophy improved 6 months after transsphenoidal resection of a pituitary adenoma.

Citations

Citations to this article as recorded by

Acromegaly presenting with normal insulin-like growth factor-1 levels in a patient with advanced liver cirrhosis
Ciara Kilcoyne, Kevin Burke, Michael W O’Reilly, Masood Iqbal, Mark Sherlock
BMJ Case Reports.2026; 19(2): e266505. CrossRef
The effect of first intervention on cardiac parameters in patients with acromegaly: a systematic review
Kevin A Huynh, Jin Al-Gully, José M Montero-Cabezas, Linda E Scheffers, Marco J T Verstegen, Nienke R Biermasz, Eva C Coopmans
European Journal of Endocrinology.2025; 192(2): S1. CrossRef
From Subtle Signs to Severe Sequelae—A Century of Symptomatology and Comorbidities in the Diagnosis of GH-Secreting Pituitary Neuroendocrine Tumors: A Systematic Review
María José Ayora, Lizeth Vinueza-Mera, Santiago Aynaguano, David Poma Jimenez, Felipe Loza Hernandez, Sebastian Jara Jimenez, Jose A. Rodas, Jose E. Leon-Rojas
Diagnostics.2025; 15(17): 2137. CrossRef
Risk of Neurodegenerative Diseases in Patients With Acromegaly
Sangmo Hong, Kyungdo Han, Kyung-Soo Kim, Cheol-Young Park
Neurology.2022;[Epub] CrossRef
Levels of Serum IGF-1, HCY, and Plasma BNP in Patients with Chronic Congestive Heart Failure and Their Relationship with Cardiac Function and Short-Term Prognosis
Zhengyi Hu, Leifang Mao, Ling Wang, Weiguo Li
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Neurofibromatosis Type 1 with Concurrent Multiple Endocrine Disorders: Adenomatous Goiter, Primary Hyperparathyroidism, and Acromegaly
Shigemitsu Yasuda, Ikuo Inoue, Akira Shimada
Internal Medicine.2021; 60(15): 2451. CrossRef
Metformin stimulates IGFBP-2 gene expression through PPARalpha in diabetic states
Hye Suk Kang, Ho-Chan Cho, Jae-Ho Lee, Goo Taeg Oh, Seung-Hoi Koo, Byung-Hyun Park, In-Kyu Lee, Hueng-Sik Choi, Dae-Kyu Song, Seung-Soon Im
Scientific Reports.2016;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search